Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
The MHRA published the findings of the National Commission into the Regulation of AI in Healthcare's Call for Evidence, the most substantial assessment yet of how the UK should regulate AI in health and care. The Commission is the independent advisory group…
Hospices across England are being offered access to a new NHS-backed AI programme designed to give doctors and nurses more time with patients during the final stages of life.
The initiative will provide selected hospices with free access to CLEARnotes,…
Attendees
Sponsors and Exhibitors
Contact us